Spots Global Cancer Trial Database for Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)
Official Title: A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC)
Study ID: NCT01137968
Conditions
Study Description
Brief Summary: The purpose of this is to evaluate the efficacy and safety of imetelstat (GRN163L) as maintenance therapy for patients with advanced stage NSCLC who have not progressed after 4 cycles of platinum based therapy. Participants will be randomized in a 2:1 ratio to imetelstat + standard of care versus standard of care alone. Participants who received bevacizumab with their induction chemotherapy will continue to receive bevacizumab on this study.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Achieve Clinical Research, Llc, Birmingham, Alabama, United States
Clearview Cancer Institute, Huntsville, Alabama, United States
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
Cancer Care Associates of Fresno Medical Group Inc, Fresno, California, United States
St. Joseph's Hospital, Orange, California, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
University of Colorado Denver School of Medicine, Aurora, Colorado, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Integrated Community Oncology Network, Jacksonville, Florida, United States
H. Moffitt Lee Cancer Center, Tampa, Florida, United States
Ingalls Memorial Hospital, Harvey, Illinois, United States
Cancer Center of Kansas, Wichita, Kansas, United States
Montgomery Cancer Center, Mt. Sterling, Kentucky, United States
Auerbach Hematology Oncology, Baltimore, Maryland, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Hematology Oncology Centers, Billings, Montana, United States
Blumenthal Cancer Center, Charlotte, North Carolina, United States
Kaiser Northwest, Portland, Oregon, United States
South Carolina Oncology Associates, Columbia, South Carolina, United States
The Jones Clinic, Germantown, Tennessee, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Scott and White Memorial Hospital (Texas A & M), Temple, Texas, United States
Swedish Cancer Institute, Seattle, Washington, United States
Northwest Medical Specialties, Tacoma, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Hôpital Charles Lemoyne, Greenfield Park, Quebec, Canada
Hospital Notre-Dame, Montreal, Quebec, Canada
Krankenhaus Grosshansdorf, Grosshansdorf, Hamburg, Germany
Asklepios Klinik Gauting GmbH, Gauting, Munich, Germany
Klinikum rechts der Isar der TU München, Munchen, Munich, Germany
Krankenhaus Nordwest, Frankfurt, , Germany
Universitaetsklinikum Mainz, Mainz, , Germany
Contact Details
Name: Joan Schiller, MD
Affiliation: University of Texas
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
